Home › Trial NCT04982289
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
- Trial IDNCT04982289
- StatusWithdrawn
- PhasePhase 2
- Study typeInterventional
- SponsorAlexion Pharmaceuticals, Inc.
- Enrollment—
- Start date2022-01-01
- ConditionsGeneralized Myasthenia Gravis
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.